IP Verse

Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders - EP3716992

The patent EP3716992 was granted to Regeneron Pharmaceuticals on Aug 10, 2022. The application was originally filed on Nov 29, 2018 under application number EP18825837A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3716992

REGENERON PHARMACEUTICALS
Application Number
EP18825837A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Jul 8, 2022
Grant Date
Aug 10, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGENMay 10, 2023SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
MAIWALDMay 10, 2023MAIWALDWITHDRAWN
BOULT WADE TENNANTMay 9, 2023BOULT WADE TENNANTADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 5, 2023WICHMANNADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2007190058
DESCRIPTIONUS7087411
DESCRIPTIONUS7300563
DESCRIPTIONUS7303746
DESCRIPTIONUS7303748
DESCRIPTIONUS7306799
DESCRIPTIONUS7396664
DESCRIPTIONWO0075319
INTERNATIONAL-SEARCH-REPORTUS2005260203
INTERNATIONAL-SEARCH-REPORTWO2012097019
INTERNATIONAL-SEARCH-REPORTWO2014203183
OPPOSITIONUS2013295094
OPPOSITIONUS9254338
OPPOSITIONWO2017053807
OPPOSITIONWO2019108770

Non-Patent Literature (NPL) Citations (65) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients", Br Med J, (20020000), vol. 324, pages 71 - 86-
DESCRIPTION- "Antithrombotic Trialists' Collaboration. Collaborative overview of randomized trial of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy", Br Med J, (19940000), vol. 308, pages 168 - 171-
DESCRIPTION- KLEIN et al., "Changes in Retinal Vessel Diameter and Incidence and Progression of Diabetic Retinopathy", Arch. Opthamol., (20120000), vol. 130, no. 6, pages 749 - 755-
DESCRIPTION- POWELL et al., J Pharm Sci Technol., (19980000), vol. 52, pages 238 - 311-
EXAMINATION- SELLA RUTI ET AL, "Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, (20160326), vol. 146, doi:10.1016/J.EXER.2016.03.021, ISSN 0014-4835, pages 224 - 232, XP029562862
INTERNATIONAL-SEARCH-REPORT- Anonymous, "Archive History for NCT02718326", (20170824), URL: https://clinicaltrials.gov/ct2/history/NCT02718326?V_7=View#StudyPageTop, (20190307), XP055565603 [Y] 1-43 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION", (20161201), URL: https://web.archive.org/web/20161206164049if_/https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf, (20190307), XP055565606 [X] 1-4,13,14,36-43 * the whole document * * page 1, column r, paragraph 1 * * 2.5; page 2, column l * [Y] 1-43-
INTERNATIONAL-SEARCH-REPORT- STEWART MICHAEL W, "Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug", INFLAMMATION & ALLERGY DRUG TAR, BENTHAM SCIENCE PUBLISHERS, NL, (20111201), vol. 10, no. 6, doi:10.2174/187152811798104872, ISSN 1871-5281, pages 497 - 508, XP009172512 [Y] 1-43 * the whole document *
OPPOSITION- American Academy Of Ophthalmology, Preferred Practice Pattern® Guidelines. Diabetic Retinopathy, (20160101), pages 1 - 63, XP093047288-
OPPOSITION- Anonymous, "Anti-VEGF Treatment for Prevention of PDR/DME; History of Changes for Study: NCT02634333", ClinicalTrials.gov; NCT02634333, (20151215), ClinicalTrials.gov; NCT02634333, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02634333?A=1&B=1&C=merged#StudyPageTop, XP093153385-
OPPOSITION- Anonymous, "Anti-VEGF Treatment for Prevention of PDR/DME - History of Changes for Study: NCT02634333", ClinicalTrials.gov; NCT02634333, (20180823), ClinicalTrials.gov; NCT02634333, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02634333?A=25&B=25&C=merged#StudyPageTop, XP093164553-
OPPOSITION- Anonymous, "Archive History for NCT02718326. Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Non proliferative Diabetic Retinopathy (NPDR) (PANORAMA)", Clinical Trials gov archive, (20200715), pages 1 - 11, Clinical Trials gov archive, (20230516), XP093047300-
OPPOSITION- Anonymous, "Eylea aflibercept injection - approval package", CENTER FOR DRUG EVALUATION AND RESEARCH; APPLICATION NUMBER: 125387Orig1s048, (20150325), CENTER FOR DRUG EVALUATION AND RESEARCH; APPLICATION NUMBER: 125387Orig1s048, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125387Orig1s048.pdf, XP093153489-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial", Regeneron, (20180319), Regeneron, URL: https://newsroom.regeneron.com/node/12936/pdf, XP093153483-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial", Regeneron Pharmaceuticals, Inc., (20180319), Regeneron Pharmaceuticals, Inc., URL: https://www.prnewswire.com/news-releases/eylea-aflibercept-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-300615723.html, XP093164529-
OPPOSITION- Anonymous, "EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON- PROLIFERATIVE DIABETIC RETINOPATHY TRIAL", Regeneron Press release, (20180319), pages 1 - 4, XP093047273-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection, for intravitreal use - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20230201), FDA, XP093153361-
OPPOSITION- Anonymous, " EYLEA® (aflibercept) Injection - HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, (20170501), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125387s054lbl.pdf, XP093164525-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)", Regeneron, (20140729), Regeneron, URL: https://newsroom.regeneron.com/node/11836/pdf, XP093153482-
OPPOSITION- Anonymous, "EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)", Regeneron Press Release, (20150325), Regeneron Press Release, URL: https://newsroom.regeneron.com/node/12026/pdf, XP093153369-
OPPOSITION- Anonymous, "FDA Approves Genentech's Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States", Genentech, (20170417), Genentech, URL: https://www.gene.com/media/press-releases/14661/2017-04-17/fda-approves-genentechs-lucentis-ranibiz, XP093164545-
OPPOSITION- Anonymous, "FDA Approves Genentech's Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States", Press Release, (20170417), Press Release, URL: https://www.gene.com/media/press-releases/14661/2017-04-17/fda-approves-genentechs-lucentis-ranibiz, XP093153376-
OPPOSITION- Anonymous, "FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy ", Press Release, (20180101), Press Release, URL: https://www.amd-fruehdiagnose.de/eylea/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy.htm, XP093153381-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - EYLEA™ (aflibercept) Injection", Regeneron Pharmaceuticals, Inc., (20161001), pages 1 - 8, XP093047258-
OPPOSITION- Anonymous, "Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME) - History of Changes for Study: NCT01331681", ClinicalTrials.gov; NCT01331681, (20160320), ClinicalTrials.gov; NCT01331681 , URL: https://classic.clinicaltrials.gov/ct2/history/NCT01331681?A=32&B=32&C=merged#StudyPageTop, XP093164541-
OPPOSITION- Anonymous, "Lucentis - ranibizumab - Approval Package", CENTER FOR DRUG EVALUATION AND RESEARCH; APPLICATION NUMBER: 125156Orig1s114, (20170415), CENTER FOR DRUG EVALUATION AND RESEARCH; APPLICATION NUMBER: 125156Orig1s114 , URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/125156Orig1s114.pdf, XP093153495-
OPPOSITION- Anonymous, "LUCENTIS® (ranibizumab injection) for intravitreal injection - HIGHLIGHTS OF PRESCRIBING INFORMATION ", FDA, (20170401), FDA, XP093153391-
OPPOSITION- Anonymous, "Record History | ver. 21: 2017-10-27 | NCT02634333 | ClinicalTrials.gov", (20171027), URL: https://www.clinicaltrials.gov/study/NCT02634333?tab=history&a=21, (20231025), XP093094923-
OPPOSITION- Anonymous, "Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema (VISTA DME) - History of Changes for Study: NCT01363440", ClinicalTrials:gov; NCT01363440, (20160425), ClinicalTrials:gov; NCT01363440, URL: https://classic.clinicaltrials.gov/ct2/history/NCT01363440?A=11&B=11&C=merged#StudyPageTop, XP093164544-
OPPOSITION- Anonymous, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA); History of Changes for Study: NCT02718326", Clinicaltrials.gov; NCT02718326, (20160502), Clinicaltrials.gov; NCT02718326, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02718326?A=2&B=2&C=merged#StudyPageTop, XP093153349-
OPPOSITION- Anonymous, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA); History of Changes for Study: NCT02718326", ClinicalTrials.gov; NCT02718326, (20161129), ClinicalTrials.gov; NCT02718326, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02718326?A=4&B=4&C=merged#StudyPageTop, XP093153352-
OPPOSITION- Anonymous, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA); History of Changes for Study: NCT02718326", ClinicalTrials.gov; NCT02718326, (20170824), ClinicalTrials.gov; NCT02718326, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02718326?A=7&B=7&C=merged#StudyPageTop, XP093153463-
OPPOSITION- Anonymous, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA) - History of Changes for Study: NCT02718326", ClinicalTrials.gov; NCT02718326, (20170824), ClinicalTrials.gov; NCT02718326, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02718326?A=7&B=7&C=merged#StudyPageTop, XP093164551-
OPPOSITION- Anonymous, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA) - History of Changes for Study: NCT02718326", ClinicalTrials.gov; NCT02718326, (20180518), ClinicalTrials.gov; NCT02718326, URL: https://classic.clinicaltrials.gov/ct2/history/NCT02718326?A=8&B=8&C=merged#StudyPageTop, XP093164547-
OPPOSITION- Bressler, "Change in Diabetic Retinopathy Through 2 Years Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab", JAMA Ophthalmology, (20170401), vol. 135, no. 6, pages 558 - 568, XP093047296-
OPPOSITION- Brown David M, "Intravitreal Aflibercept Injection (IAI) for Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR): The Phase 3 PANORAMA Study", Investigative Ophthalmology & Visual Science, (20180701), vol. 59, no. 1889, pages 1 - 2, XP093047280-
OPPOSITION- Diana Shechtman, "Hold 'em of fold 'em?", (20180415), URL: https://www.reviewofoptometry.com/article/hold-em-or-fold-em, XP093153333-
OPPOSITION- M D Davis, "Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18", Investigative Ophthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (19980201), vol. 39, no. 2, ISSN 0146-0404, pages 233 - 252, XP093164509-
OPPOSITION- Muhammad Ahmed, "Efficacy of Intra-Vitreal Bevacizumab Combined with Phaco-Emulsification in the Prophylaxis of Macular Edema in Patients with Non-Proliferative Diabetic Retinopathy", APMC-303, (20160401), vol. 10, no. 2, pages 58 - 62, XP093153241-
OPPOSITION- Rajiv Raman, "Diabetic Macular Edema", Sci J Med & Vis Foun, (20150601), vol. 33, no. 2, pages 50 - 56, XP093153235-
OPPOSITION- Stewart Michael W, "Treatment of diabetic retinopathy: Recent advances and unresolved challenges", World J Diabetes, (20160825), vol. 7, no. 16, pages 333 - 341, XP093047262-
OPPOSITION- Virgili G, Et Al, "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis (Review)", Cochrane Database of Systematic Reviews, Wiley, (20170101), pages 1 - 156, XP093047267-
OPPOSITION- "Photocoagulation for Diabetic Macular Edema : Early Treatment Diabetic Retinopathy Study Report Number 1 Early Treatment Diabetic Retinopathy Study Research Group", Archives of Ophthalmology, American Medical Association, United States, United States , (19851201), vol. 103, no. 12, doi:10.1001/archopht.1985.01050120030015, ISSN 0003-9950, pages 1796 - 1806, XP009553578
OPPOSITION- Adam R Glassman, "Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy - A Randomized Clinical Trial ", JAMA, American Medical Association, vol. 314, no. 20, doi:10.1001/jama.2015.15217, ISSN 0098-7484, pages 2137 - 2146, XP093153341
OPPOSITION- Adam R Glassman, "Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy - A Randomized Clinical Trial ", JAMA; TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01489189, doi:10.1001/jama.2015,15217, pages 2137 - 2146, JAMA; TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01489189, XP093153341
OPPOSITION- Brown David M., Wykoff Charles C., Boyer David, Heier Jeffrey S., Clark W. Lloyd, Emanuelli Andres, Higgins Patrick M., Singer Michael, Weinreich David M., Yancopoulos George D., Berliner Alyson J., Chu Karen, Reed Kimberly, Cheng Yenchieh, Vitti Robert, "Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy : Results From the PANORAMA Randomized Clinical Trial", JAMA Ophthalmology, American Medical Association, US, US , (20210901), vol. 139, no. 9, doi:10.1001/jamaophthalmol.2021.2809, ISSN 2168-6165, pages 946 - 955, XP093153250
OPPOSITION- David M. Brown, "Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy : Results From the PANORAMA Randomized Clinical Trial", JAMA Ophthalmology, American Medical Association, US, US , (20210901), vol. 139, no. 9, doi:10.1001/jamaophthalmol.2021.2809, ISSN 2168-6165, pages 946 - 955, XP093153250
OPPOSITION- STEWART, "A review of Ranibizumab for the 2017 treatment of diabetic retinopathy", Ophthalmol Ther, (20170000), vol. 6, doi:10.1007/s40123-017-0083-9, pages 33 - 47, XP093080507
OPPOSITION- Noura Al Qassimi, "Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology", Ophthalmology and Therapy, (20221001), vol. 11, no. 5, doi:10.1007/s40123-022-00547-2, ISSN 2193-8245, pages 1937 - 1950, XP093153343
OPPOSITION- KOROBELNIK et al., "Intravitreal aflibercept for 2014 diabetic macular edema", Ophthalmol, (20140000), vol. 121, doi:10.1016/j.ophtha.2014.05.006, pages 2247 - 2254, XP002791242
OPPOSITION- David M. Brown, "Intravitreal Aflibercept for Diabetic Macular Edema", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20151001), vol. 122, no. 10, doi:10.1016/j.ophtha.2015.06.017, ISSN 0161-6420, pages 2044 - 2052, XP093153337
OPPOSITION- DHOOT et al., "Baseline factors affecting changes 2017 in diabetic retinopathy severity scale score after intravitreal aflibercept or laser for diabetic macular edema", Ophthalmology, (20170000), vol. 125, no. 1, doi:10.1016/j.ophtha.2017.06.029, pages 51 - 56, XP085314022
OPPOSITION- Andrew P. Schachat, "Anti-Vascular Endothelial Growth Factor Drugs to Reduce Diabetic Retinopathy Progression", OPHTHALMOLOGY RETINA 20171101 ELSEVIER INC USA, (20181001), vol. 2, no. 10, doi:10.1016/j.oret.2018.08.004, ISSN 2468-6530, pages 985 - 987, XP093164515
OPPOSITION- J.H. González-Cortés, "Treatment of Diabetic Macular Edema (DME): Shifting paradigms", Medicina Universitaria, Facultad de Medicina de la Universidad Autonoma de Nuevo Leon, (20151001), vol. 17, no. 69, doi:10.1016/j.rmu.2016.04.001, ISSN 1665-5796, pages 243 - 247, XP093153217
OPPOSITION- SIVAPRASAD et al., "Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial", Lancet, (20170000), vol. 389, doi:10.1016/S0140-6736(17)31193-5, pages 2193 - 2203, XP085051769
OPPOSITION- Sivaprasad Sobha; Prevost A Toby; Vasconcelos Joana C; Riddell Amy; Murphy Caroline; Kelly Joanna; Bainbridge James; Tudor-Edwards Rhiannon; Hopkins David; Hykin Philip, "Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20170507), vol. 389, no. 10085, doi:10.1016/S0140-6736(17)31193-5, ISSN 0140-6736, pages 2193 - 2203, XP085051769
OPPOSITION- Benjamin J. Ernst; Gerardo García‐Aguirre; Scott C. N. Oliver; Jeffrey L. Olson; Naresh Mandava; Hugo Quiroz‐Mercado, "Intravitreal bevacizumab versus panretinal photocoagulation for treatment‐naïve proliferative and severe nonproliferative diabetic retinopathy", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Wiley-Blackwell Munksgaard, Denmark, Denmark , (20120309), vol. 90, no. 7, doi:10.1111/j.1755-3768.2011.02364.x, ISSN 1755-375X, pages e573 - e574, XP072391418
OPPOSITION- Sobha Sivaprasad, "Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial", BMJ Open, BMJ Publishing Group, London, UK, London, UK , (20150508), vol. 5, no. 9, doi:10.1136/bmjopen-2015-008405, ISSN 2044-6055, page e008405, XP093164513
OPPOSITION- De Oliveira Dias João Rafael, De Andrade Gabriel Costa, Novais Eduardo Amorim, Farah Michel Eid, Rodrigues Eduardo Büchele, "Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept", International Journal of Retina and Vitreous, (20161201), vol. 2, no. 1, doi:10.1186/s40942-016-0026-y, page 3, XP055927160
OPPOSITION- Matthew Powers, "Recent advances in the management and understanding of diabetic retinopathy", F1000Research, F1000 Research Ltd, GB, GB , (20171129), vol. 6, doi:10.12688/f1000research.12662.1, ISSN 2046-1402, page 2063, XP093153466
OPPOSITION- Mehreen Adhi, "Macular Thickness by Age and Gender in Healthy Eyes Using Spectral Domain Optical Coherence Tomography", PLOS ONE, Public Library of Science, US, US , vol. 7, no. 5, doi:10.1371/journal.pone.0037638, ISSN 1932-6203, page e37638, XP093153254
OPPOSITION- Edgar Cuervo-Lozano, "Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema", International Journal of Ophthalmology, International Council of Ophthalmology, CN, CN , (20180618), vol. 11, no. 6, doi:10.18240/ijo.2018.06.14, ISSN 2222-3959, pages 981 - 985, XP093153328
OPPOSITION- Michael W. Stewart, "The clinical utility of aflibercept for diabetic macular edema", Diabetes, Metabolic Syndrome and Obesity: targets and therapy, Dove Medical Press Ltd., GB, GB , vol. 18, no. 8, doi:10.2147/DMSO.S72792, ISSN 1178-7007, pages 473 - 482, XP093153245
OPPOSITION- Kevin Blinder, "Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)", Clinical Ophthalmology, Volume 11, doi:10.2147/OPTH.S128509, ISSN 1177-5483, pages 393 - 401, XP093153476
OPPOSITION- Stewart Michael W, "Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug", Inflammation & Allergy Drug Targets, Bentham Science Publishers, NL, NL , (20111201), vol. 10, no. 6, doi:10.2174/187152811798104872, ISSN 1871-5281, pages 497 - 508, XP009172512

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents